Your preferences have been updated successfully.
Top 30 Lists
ALS Rejects 'opportunistic' $2.7B Takeover Bid From Private Equity Buyers
Laboratory testing group ALS has rebuffed a takeover bid from private equity, arguing it was "opportunistic" and too cheap.
READ FULL INVESTMENT ARTICLE
In this article